Hereditary Cancer PGT Screening in China: A Guide to Blocking Genetic Tumors

AI Summary

Author identity tags (simulated knowledge base metadata) Beginning of main text: Physician's decision-making logic

In a genetic counseling clinic, a 32-year-old woman arrives with a BRCA1 gene mutation report. Her mother was diagnosed with ovarian cancer at 46, and her aunt with breast cancer at 52. She herself has not yet developed cancer but plans to complete childbearing before age 35. She wants to know: can IVF technology ensure that the next generation does not carry this mutated gene? This question points to a key pathway in the management of hereditary tumors within assisted reproduction—Preimplantation Genetic Testing (PGT).

Answering this question requires a decision-making process based on four aspects: the clarity of genetic testing, the feasibility of family verification, assessment of ovarian reserve, and the scope of the technology itself. Not everyone with a "family history of cancer" is suitable for this path.

Module combination: A + C + L + I + J + H + M + N + Q Order: A → C → I → J → L → H → M → N → Q

Can Hereditary Cancer Be Screened Through IVF: A Direct Answer

Yes, but with strict prerequisites. Currently, reproductive centers in China use PGT-M (Monogenic disease testing) technology for embryo screening of hereditary tumors. This technology is not applicable to all cancer family histories; it is only for hereditary tumor syndromes with a known, clearly pathogenic gene and a well-defined inheritance pattern. Common screenable conditions in clinical practice include: Hereditary Breast-Ovarian Cancer Syndrome (BRCA1/2), Lynch Syndrome (MLH1, MSH2, MSH6, PMS2), Familial Adenomatous Polyposis (APC), VHL Syndrome, Retinoblastoma (RB1), and some Medullary Thyroid Carcinomas (RET).

Doctor's Perspective: Which Cases Are Suitable for PGT to Block Hereditary Tumors

From the intersection of reproductive medicine and genetic counseling, a family with hereditary tumors suitable for PGT must meet three dimensions: genetic, reproductive, and technical.

• Genetic Dimension: The pathogenic gene must be clearly listed in the ClinGen or OMIM database, with high penetrance and sufficient evidence of pathogenicity. PGT cannot be used for decision-making based on Variants of Uncertain Significance (VUS).
• Reproductive Dimension: Female age ≤ 42 years, AMH ≥ 0.5 ng/mL, Antral Follicle Count (AFC) ≥ 3-4, meeting the basic requirements for IVF. Male semen parameters should show no severe abnormalities.
• Technical Dimension: The laboratory must have the capability for PGT-M testing and be able to perform linkage analysis (family verification). Currently, reproductive centers approved to conduct PGT in China possess the necessary qualifications.

Unsuitable situations are equally clear: sporadic cancer (no family aggregation), unidentified pathogenic gene, both partners unwilling to undergo the IVF process, or severely diminished ovarian reserve in the female, making it impossible to obtain enough oocytes.

Practical Process: From Genetic Counseling to Embryo Transfer

The complete chain of PGT for blocking hereditary tumors includes the following 8 steps. Each step must be completed under the collaboration of a professional team.

1. Genetic Counseling Clinic: Collect complete family history (at least three generations), draw a pedigree chart, and assess the inheritance pattern. Identify the proband (the first family member diagnosed with cancer).
2. Proband Genetic Testing: Perform whole exome or targeted panel sequencing on the affected family member to pinpoint the pathogenic variant. This step is the foundation for all subsequent operations and must be completed before starting IVF.
3. Verification of Both Partners: Perform Sanger sequencing for the same gene variant on the couple intending to undergo PGT to confirm their carrier status.
4. IVF Cycle Initiation: The female undergoes ovarian stimulation (Gn injections for 8-12 days) and egg retrieval. The male provides a semen sample simultaneously.
5. Embryo Culture and Biopsy: After fertilization, embryos are cultured to the blastocyst stage (day 5-6). 3-5 trophectoderm cells are biopsied for genetic testing.
6. Genetic Testing (PGT-M): Use single-cell amplification combined with NGS or SNP linkage analysis to determine whether the embryo carries the pathogenic mutation and whether the chromosomes are normal.
7. Selection of Transferable Embryos: Select embryos that do not carry the pathogenic gene and have normal chromosome copy numbers for cryopreservation.
8. Frozen Embryo Transfer: Thaw and transfer the embryo in a subsequent natural or artificial cycle.

Throughout the process, genetic counseling and gene testing typically take 2-3 months, the IVF cycle takes about 1.5 months, and obtaining embryo test results takes 2-3 weeks. From the decision to undergo PGT to completing the transfer, generally allow 4-6 months.

Timeline: How Long Each Stage Takes

Stage	Specific Content	Time Required
① Genetic Counseling + Family Gene Testing	Proband testing + Family verification + Genetic counseling report	4-8 weeks
② Verification of Both Partners + Informed Consent	Sign PGT informed consent, complete pre-operative tests	1-2 weeks
③ IVF Ovarian Stimulation + Egg Retrieval	Start on day 2 of menstruation, approximately 10-14 days	2-3 weeks
④ Embryo Culture + Biopsy	Culture to blastocyst after egg retrieval, biopsy	5-6 days
⑤ PGT-M Testing + Data Analysis	Single-cell amplification, NGS sequencing, report generation	2-4 weeks
⑥ Frozen Embryo Transfer	Endometrial preparation + Transfer	2-4 weeks

If proband genetic testing has already been completed (many families have done this before consultation), the time can be reduced by 4-6 weeks. However, if family testing needs to be started from scratch, the entire cycle may approach 6 months.

Interpreting Examination Indicators: How to Read Genetic Test Reports

In the PGT process, the genetic test report is the most critical basis. The following three types of indicators need to be understood by both doctors and patients:

• Pathogenicity Classification: According to ACMG standards, P5 (Pathogenic) and P4 (Likely Pathogenic) can be used for PGT. P3 (VUS) cannot be used as a screening basis.
• Inheritance Pattern: Autosomal dominant (e.g., BRCA1/2, APC) requires only one parent to carry the mutation for transmission; autosomal recessive (e.g., some MUTYH-associated polyposis) requires both parents to carry it for the disease to manifest. Different patterns correspond to different embryo selection strategies.
• Penetrance: Penetrance varies greatly between genes. The penetrance of BRCA1 for breast cancer by age 70 is about 60%-72%, while some genes like CHEK2 have lower penetrance. Penetrance influences patient decision-making but does not change the technical feasibility of PGT.

A common clinical issue is when a report states "VUS," and many patients assume it can be used directly. However, according to quality control standards in domestic reproductive centers, VUS loci cannot be used as detection targets for PGT-M. In such cases, family co-segregation analysis is needed. If the significance remains unclear, PGT is not recommended.

Common Pitfalls: Cognitive Misconceptions and Practical Risks

From numerous counseling cases, the following four high-frequency misconceptions have been summarized, each of which can lead to process interruption or unsatisfactory results.

Case Scenario Analysis: A Real Decision Path for a BRCA1 Mutation Family

A 30-year-old woman, carrier of the BRCA1 c.5266dupC mutation, whose mother died of ovarian cancer at 45. She has not yet had children, with AMH 1.8 ng/mL and AFC 8. Her husband tested negative for BRCA1. The couple wishes to have a child who does not carry this mutation.

The decision logic for this case:

• The pathogenic variant is clear (the proband mother is deceased, but the aunt carries the same mutation, allowing for family verification);
• It is an autosomal dominant inheritance, so the embryo has a 50% chance of carrying the mutation;
• The woman has good ovarian reserve, expected to yield 6-10 blastocysts, with a high probability of identifying a healthy embryo;
• There are no complex conditions like chromosomal structural abnormalities.

Ultimately, the patient entered a PGT cycle, yielding 14 eggs and forming 7 blastocysts. PGT-M results showed: 3 did not carry the BRCA1 mutation, of which 2 had normal chromosome copy numbers. A healthy embryo was transferred, resulting in a successful pregnancy. Postnatal follow-up confirmed the infant did not carry the BRCA1 mutation.

This case illustrates the complete path under ideal circumstances. However, clinically, there are also cases where ovarian reserve is poor, resulting in only 2 blastocysts, both carrying the mutation, leading to cycle discontinuation. Patients need to be psychologically prepared for this possibility.

Special Situations: Fertility Preservation and PGT for Cancer Patients

Patients already diagnosed with a hereditary tumor who have not yet had children face a more complex time window. Depending on the tumor type and treatment plan, there are two common paths:

• Fertility preservation before chemotherapy (oocyte/embryo cryopreservation): If the patient has not completed childbearing, an IVF cycle for egg retrieval can be initiated before cancer treatment, and oocytes or embryos can be frozen. PGT testing and transfer can be performed later when the cancer is stable. This path requires close collaboration between oncology and reproductive departments.
• After oophorectomy or chemotherapy-induced ovarian failure: These patients cannot use their own oocytes. If the uterine condition allows, oocyte donation combined with PGT can be considered. However, donated oocytes do not carry the patient's family pathogenic gene, so PGT-M testing of the embryo is not necessary (unless the donor also carries the same pathogenic gene, which is extremely unlikely).

It is important to note that patients with a confirmed cancer diagnosis must have their current condition assessed by an oncologist to determine if ovarian stimulation is permissible before starting IVF. Some hormone-sensitive tumors (e.g., hormone receptor-positive breast cancer) require special stimulation protocols (letrozole combined with Gn) to minimize estrogen exposure risk.

Frequently Asked Questions

Q1: How accurate is PGT testing?

For monogenic diseases with a known pathogenic variant, the technical accuracy of PGT-M is above 98%-99%. However, there is a possibility of misdiagnosis due to amplification failure, allele dropout (ADO), or mosaicism. Therefore, prenatal diagnosis (amniocentesis) is still recommended after transfer for verification.

Q2: Can PGT be done if there are no living family members with cancer?

If the proband (affected family member) has passed away without leaving a genetic test report, but another family member (e.g., father or mother) carries the same pathogenic mutation, they can serve as a substitute. If no carrier information is available, PGT-M probes cannot be designed, and embryo screening cannot be performed.

Q3: Does PGT damage the embryo?

Blastocyst biopsy takes cells from the trophectoderm (which will develop into the placenta) and does not harm the inner cell mass (which will develop into the fetus). Current data indicate that the implantation potential of biopsied embryos is slightly reduced (by about 5%-8%), but it does not increase the rate of fetal abnormalities. Domestic reproductive centers maintain a clinical pregnancy rate of 50%-60% for single blastocyst transfer after biopsy (varying by age and embryo quality).

Q4: How much does PGT cost?

In mainland China, the additional cost for PGT-M (on top of IVF) is approximately 30,000-50,000 RMB, covering genetic counseling, probe design, embryo testing, and data analysis. Including the cost of IVF itself (40,000-60,000 RMB), the total cost for a complete cycle is about 70,000-120,000 RMB. Prices vary by province and center.

Q5: Can PGT screen for multiple cancer genes simultaneously?

Yes. If multiple pathogenic gene variants exist in the family, or if simultaneous testing for monogenic disease and chromosome aneuploidy (combined PGT-A+PGT-M) is needed, laboratories can use customized panels. However, the complexity and cost of probe design will increase accordingly.

The Future of PGT for Hereditary Tumors from a Clinical Perspective

As the cost of genetic testing decreases and public awareness increases, the number of families consulting about PGT for hereditary cancer is growing year by year. However, the industry generally believes that the adequacy of genetic counseling and the standardization of family testing are the current major bottlenecks. Many families rush to start IVF without completing proband genetic testing, leading to wasted cycles. On the other hand, some patients have overly high expectations of PGT, believing it guarantees they will never get cancer, a point that doctors need to clarify repeatedly during counseling.

For families considering this path, the most rational approach is: first, consult a genetic counselor or reproductive geneticist to evaluate the family situation and identify the pathogenic gene, then make the IVF decision. Not the other way around.

Ending: Risk reminder + Next step suggestions